High-quality protein is a key in advancing various fields, from drug development to cancer research. In an important case study, our expertise in protein design and production played a pivotal role in identifying critical targets for biological research, especially in the context of pancreatic ductal adenocarcinoma (PDAC). We determined the BAG3 receptor and IFITM-2 as key players in PDAC growth and metastasis, and further developed an anti-BAG3 antibody with promising therapeutic potential, effectively reducing tumor growth and preventing metastasis in various mouse models. This case study exemplifies our commitment to providing innovative protein solutions that drive groundbreaking research and improved cancer treatments.
Our results were further validated through a complementary Co-IP approach involving IFITM2. Moreover, the RNAi approach demonstrated that silencing IFITM2 effectively abrogated BAG3-induced signaling in macrophages, leading to reduced IL-6 release, and decreased AKT and p38 phosphorylation. This study underscores the critical importance of target identification in unraveling the intricate mechanisms of pancreatic cancer growth and metastasis, paving the way for potential therapeutic interventions.
References :
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages
ROSATI E et al., Nature, 2015
